Items where Author is "Ballinger, M."
 | Up a level |
Other
Schulz, C. and Chu, P. and Berardo, C. G. and Karthuria, B. and Foo, J. and Morel, C. and Watkins, C. and Ballinger, M. and Gandara, D. R. (2018) Fractional polynomial network meta-analysis: A different approach to indirectly assess the comparative efficacy of 2L+cancer immunotherapy (CIT) treatments for metastatic NSCLC. OXFORD UNIV PRESS, OXFORD.
Schulz, C. and Schmid, P. and Hedge, P. and Zou, W. and Kowanetz, M. and Mariathasan, S. and Gadgeel, S. and Powles, T. and Van Der Heijden, M. S. and Fasso, M. and O'Hear, C. and Ballinger, M. and Fine, G. and Sandler, A. and Chen, D. and Hodi, S. F. (2017) Association of PD-L2 expression in human tumors with atezolizumab activity. KARGER, BASEL.
Schulz, C. and Spira, A. and Park, K. and Mazieres, J. and Vansteenkiste, J. and Ballinger, M. and Waterkamp, D. and Fehrenbacher, L. (2016) Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab vs docetaxel in patients with advanced NSCLC (POPLAR). KARGER, BASEL.
